X ie Liangzhi is the chairman and president of Sinocelltech Group, a prominent Beijing-based biotechnology company specializing in the research, development, and industrialization of biological products. A distinguished scholar and engineer, Xie holds a Ph.D. in chemical engineering from the Massachusetts Institute of Technology (MIT). His early career was defined by significant experience in the United States, where he worked as a senior engineer for pharmaceutical giant Merck & Co. from 1997 to 2002, gaining valuable expertise in global drug development standards.

Returning to China to contribute to its burgeoning biotech sector, Xie founded Sinocelltech in 2002. Under his leadership, the company has focused on developing monoclonal antibodies, recombinant proteins, and vaccines, becoming a key player in China's biopharmaceutical landscape. The company listed on the Shanghai Stock Exchange's STAR Market, cementing Xie's status as a leader in the industry. His wealth is derived from his controlling stake in this innovative enterprise.